2026-04-29T07:24:20Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/51122024-09-27T09:16:02Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud
author
Lopez-Santalla, Mercedes
author
Mancheno-Corvo, Pablo
author
Escolano, Amelia
author
Menta, Ramon
author
DelaRosa, Olga
author
Luis Abad, Jose
author
Buscher, Dirk
author
Redondo, Juan Miguel
author
Bueren, Juan A.
author
Dalemans, Wilfried
author
Lombardo, Eleuterio
author
Garin, Marina I.
funder
European Commission
2017-10-20T10:23:11Z
2017-10-20T10:23:11Z
2017
Front Immunol. 2017; 8:638
1664-3224
http://hdl.handle.net/20.500.12105/5112
28642759
10.3389/fimmu.2017.00638
Frontiers in Immunology
Mesenchymal stem cells (MSCs) have a large potential in cell therapy for treatment of inflammatory and autoimmune diseases, thanks to their immunomodulatory properties. The encouraging results in animal models have initiated the translation of MSC therapy to clinical trials. In cell therapy protocols with MSCs, administered intravenously, several studies have shown that a small proportion of infused MSCs can traffic to the draining lymph nodes (LNs). This is accompanied with an increase of different types of regulatory immune cells in the LNs, suggesting the importance of migration of MSCs to the LNs in order to contribute to immunomodulatory response. Intranodal (IN), also referred as intralymphatic, injection of cells, like dendritic cells, is being proposed in the clinic for the treatment of cancer and allergy, showing that this route of administration is clinically safe and efficient. In this study, we investigated, for the first time, the biodistribution and the efficacy of Luciferase+adipose-derived MSCs (Luci-eASCs), infused through the inguinal LNs (iLNs), in normal mice and in inflamed mice with colitis. Most of the LucieASCs remain in the iLNs and in the adipose tissue surrounding the inguinal LNs. A small proportion of Luci-eASCs can migrate to other locations within the lymphatic system and to other tissues and organs, having a preferential migration toward the intestine in colitic mice. Our results show that the infused Luci-eASCs protected 58\% of the mice against induced colitis. Importantly, a correlation between the response to eASC treatment and a higher accumulation of eASCs in popliteal, parathymic, parathyroid, and mesenteric LNs were found. Altogether, these results suggest that IN administration of eASCs is feasible and may represent an effective strategy for cell therapy protocols with human adipose-derived MSCs in the clinic for the treatment of immune-mediated disorders.
eng
Adipose-derived mesenchymal stem cells
Intranodal therapy
Colitis
Biodistribution
Efficacy
Immunomodulation
SYSTEMIC-LUPUS-ERYTHEMATOSUS
INFLAMMATORY-BOWEL-DISEASE
STROMAL CELLS
LYMPHOCYTE-PROLIFERATION
EXPERIMENTAL ARTHRITIS
DENDRITIC CELLS
CLINICAL-TRIAL
ANIMAL-MODELS
IN-VITRO
THERAPY
Biodistribution and efficacy of human adipose-Derived Mesenchymal stem cells Following intranodal administration in experimental colitis
journal article
URL
https://repisalud.isciii.es/bitstreams/56ef4f1e-9c6c-4ac5-a39d-9a35c2ed1cd0/download
File
MD5
e23d4be42b1307becfb2d20191846064
3459174
application/pdf
BiodistributionAndEfficacyOfHuman_2017
URL
https://repisalud.isciii.es/bitstreams/073767b6-5760-4e00-9c2d-9276aa1ad71b/download
File
MD5
7c672e450e45607b5eca7d6e29168f0f
60272
text/plain
BiodistributionAndEfficacyOfHuman_2017.txt